{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:42:50Z","timestamp":1778539370015,"version":"3.51.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study aimed to evaluate the potential cost-effectiveness of implementing a prediction tool for estimating mild cognitive impairment (MCI) to dementia conversion risk. A decision-analytic model was developed to compare the costs and effects of current practice for subjects with MCI to a situation in which the risk of dementia is estimated using a prediction tool. Different scenarios in terms of prediction horizons, prediction characteristics (e.g. sensitivity and specificity), and treatment availability were evaluated. The model was applied to the AI-Mind tool, which is currently under development for predicting MCI to dementia risk. In a clinical situation, with no widely applicable and highly effective disease-modifying treatment available, implementing a dementia risk prediction tool leads to lower QALYs and higher costs compared to current practice without such a prediction tool (9.32 vs 9.36 QALYs and \u20ac115,837 vs \u20ac115,032 for the analyses in this paper). This loss in QALYs was caused by the impact on quality of life associated with predicted dementia conversion risk. Risk prediction followed by efficient treatment strategies based on the predicted risk could lead to a cost-effective alternative in case of specific treatment characteristics. These findings suggest that standalone (i.e. without highly effective treatment options) use of a dementia risk prediction tool may not be cost-effective, but it could result in a cost-effective alternative in combination with a treatment with favourable efficacy and cost profile.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s11357-025-02032-7","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T14:45:45Z","timestamp":1771857945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating dementia risk prediction in mild cognitive impairment: an early health technology assessment of the AI-Mind tool"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3054-8459","authenticated-orcid":false,"given":"Robin J.","family":"Vermeulen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel G. M. Olde","family":"Rikkert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Handels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira R. J. Hebold","family":"Haraldsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Renvall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo M.","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camillo","family":"Marra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Maest\u00fa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maroeska M.","family":"Rovers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim M.","family":"Govers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"2032_CR1","unstructured":"(OECD) OfEC-oaD. Health expenditure and financing 2024 [Available from: https:\/\/data-explorer.oecd.org\/vis?lc=en&fs[0]=Topic%2C1%7CHealth%23HEA%23%7CHealth%20expenditure%20and%20financing%23HEA_EXP%23&pg=0&fc=Topic&bp=true&snb=4&vw=tl&df[ds]=dsDisseminateFinalDMZ&df[id]=DSD_SHA%40DF_SHA&df[ag]=OECD.ELS.HD&df[vs]=1.0&dq=.A.EXP_HEALTH.PT_B1GQ._T.._T.._T...&pd=1970%2C2023&to[TIME_PERIOD]=false&ly[cl]=TIME_PERIOD&ly[rw]=REF_AREA. Accessed 16 Oct 2024."},{"issue":"10","key":"2032_CR2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.15171\/ijhpm.2019.36","volume":"8","author":"JPC Grutters","year":"2019","unstructured":"Grutters JPC, Govers T, Nijboer J, Tummers M, van der Wilt GJ, Rovers MM. Problems and promises of health technologies: the role of early health economic modeling. Int J Health Policy Manag. 2019;8(10):575\u201382.","journal-title":"Int J Health Policy Manag"},{"issue":"7","key":"2032_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40273-017-0509-1","volume":"35","author":"MJ I","year":"2017","unstructured":"I MJ, Koffijberg H, Fenwick E, Krahn M. Emerging use of early health technology assessment in medical product development: a scoping review of the literature. Pharmacoeconomics. 2017;35(7):727\u201340.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"2032_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3233\/JAD-190426","volume":"70","author":"YH El-Hayek","year":"2019","unstructured":"El-Hayek YH, Wiley RE, Khoury CP, Daya RP, Ballard C, Evans AR, et al. Tip of the iceberg: assessing the global socioeconomic costs of Alzheimer\u2019s disease and related dementias and strategic implications for stakeholders. J Alzheimers Dis. 2019;70(2):323\u201341.","journal-title":"J Alzheimers Dis"},{"key":"2032_CR5","unstructured":"World Health Organization. Global status report on the public health response to dementia. Geneva: World Health Organization; 2021. p. 137. Available from:\nhttps:\/\/www.who.int\/publications\/i\/item\/9789240033245?utm_source=chatgpt.com."},{"issue":"3","key":"2032_CR6","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","volume":"90","author":"RC Petersen","year":"2018","unstructured":"Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, Ganguli M, Gloss D, et al. Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(3):126\u201335.","journal-title":"Neurology"},{"key":"2032_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101580","volume":"51","author":"A Nandi","year":"2022","unstructured":"Nandi A, Counts N, Chen S, Seligman B, Tortorice D, Vigo D, et al. Global and regional projections of the economic burden of Alzheimer\u2019s disease and related dementias from 2019 to 2050: a value of statistical life approach. EClinicalMedicine. 2022;51:101580.","journal-title":"EClinicalMedicine"},{"key":"2032_CR8","unstructured":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105-e25."},{"issue":"10","key":"2032_CR9","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.mayocp.2014.06.019","volume":"89","author":"DS Knopman","year":"2014","unstructured":"Knopman DS, Petersen RC. Mild cognitive impairment and mild dementia: a clinical perspective. Mayo Clin Proc. 2014;89(10):1452\u20139.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2032_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183\u201394.","journal-title":"J Intern Med"},{"issue":"4","key":"2032_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1600-0447.2008.01326.x","volume":"119","author":"AJ Mitchell","year":"2009","unstructured":"Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia\u2013meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119(4):252\u201365.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"2032_CR12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000354370","volume":"3","author":"A Ward","year":"2013","unstructured":"Ward A, Tardiff S, Dye C, Arrighi HM. Rate of conversion from prodromal Alzheimer\u2019s disease to Alzheimer\u2019s dementia: a systematic review of the literature. Dement Geriatr Cogn Disord Extra. 2013;3(1):320\u201332.","journal-title":"Dement Geriatr Cogn Disord Extra"},{"key":"2032_CR13","doi-asserted-by":"crossref","unstructured":"Chen Y, Qian X, Zhang Y, Su W, Huang Y, Wang X, et al. Prediction models for conversion from mild cognitive impairment to Alzheimer\u2019s disease: a systematic review and meta-analysis. Front Aging Neurosci. 2022;14:840386.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/35493941\/","DOI":"10.3389\/fnagi.2022.840386"},{"issue":"4","key":"2032_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/jnnp-2018-318212","volume":"90","author":"XH Hou","year":"2019","unstructured":"Hou XH, Feng L, Zhang C, Cao XP, Tan L, Yu JT. Models for predicting risk of dementia: a systematic review. J Neurol Neurosurg Psychiatry. 2019;90(4):373\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2032_CR15","unstructured":"AI-Mind. Artificial intelligence for dementia prevention. [Available from: https:\/\/www.ai-mind.eu\/. Accessed 14 Aug 2025."},{"key":"2032_CR16","doi-asserted-by":"publisher","first-page":"1289406","DOI":"10.3389\/fnbot.2023.1289406","volume":"17","author":"IH Haraldsen","year":"2023","unstructured":"Haraldsen IH, Hatlestad-Hall C, Marra C, Renvall H, Maest\u00fa F, Acosta-Hern\u00e1ndez J, et al. Intelligent digital tools for screening of brain connectivity and dementia risk estimation in people affected by mild cognitive impairment: the AI-Mind clinical study protocol. Front Neurorobot. 2023;17:1289406.","journal-title":"Front Neurorobot"},{"issue":"4","key":"2032_CR17","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3233\/JAD-180638","volume":"66","author":"M Smedinga","year":"2018","unstructured":"Smedinga M, Tromp K, Schermer MHN, Richard E. Ethical arguments concerning the use of Alzheimer\u2019s disease biomarkers in individuals with no or mild cognitive impairment: a systematic review and framework for discussion. J Alzheimers Dis. 2018;66(4):1309\u201322.","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"2032_CR18","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.jval.2021.12.003","volume":"25","author":"JPC Grutters","year":"2022","unstructured":"Grutters JPC, Kluytmans A, van der Wilt GJ, Tummers M. Methods for early assessment of the societal value of health technologies: a scoping review and proposal for classification. Value Health. 2022;25(7):1227\u201334.","journal-title":"Value Health"},{"issue":"1","key":"2032_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139.","journal-title":"Value Health"},{"issue":"4","key":"2032_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Corro Ramos I, van Voorn GA, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349\u201361.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"2032_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0525-9","volume":"11","author":"D Bertens","year":"2019","unstructured":"Bertens D, Vos S, Kehoe P, Wolf H, Nobili F, Mendon\u00e7a A, et al. Use of mild cognitive impairment and prodromal AD\/MCI due to AD in clinical care: a European survey. Alzheimers Res Ther. 2019;11(1):74.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"2032_CR22","volume":"8","author":"JP Hlavka","year":"2019","unstructured":"Hlavka JP, Mattke S, Liu JL. Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer\u2019s treatment. Rand Health Q. 2019;8(3):2.","journal-title":"Rand Health Q"},{"issue":"1","key":"2032_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"key":"2032_CR24","unstructured":"FDA. Drugs@FDA: FDA-approved drugs [Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process. Accessed 24 Dec 2024."},{"key":"2032_CR25","unstructured":"Commission E. Commission authorises medicine for treatment of early Alzheimer\u2019s disease 2025 [Available from: https:\/\/ec.europa.eu\/newsroom\/sante\/items\/879055\/en. Accessed 25 Apr 2025."},{"issue":"6","key":"2032_CR26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"issue":"1","key":"2032_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40273-022-01212-z","volume":"41","author":"L J\u00f6nsson","year":"2023","unstructured":"J\u00f6nsson L, Tate A, Frisell O, Wimo A. The costs of dementia in Europe: an updated review and meta-analysis. Pharmacoeconomics. 2023;41(1):59\u201375.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"2032_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12955-017-0591-2","volume":"15","author":"C Reed","year":"2017","unstructured":"Reed C, Barrett A, Lebrec J, Dodel R, Jones RW, Vellas B, et al. How useful is the EQ-5D in assessing the impact of caring for people with Alzheimer\u2019s disease? Health Qual Life Outcomes. 2017;15(1):16.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"2032_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/acps.12336","volume":"130","author":"AJ Mitchell","year":"2014","unstructured":"Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis. Acta Psychiatr Scand. 2014;130(6):439\u201351.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"2032_CR30","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3233\/JAD-191055","volume":"75","author":"A Wimo","year":"2020","unstructured":"Wimo A, Handels R, Winblad B, Black CM, Johansson G, Salomonsson S, et al. Quantifying and describing the natural history and costs of Alzheimer\u2019s disease and effects of hypothetical interventions. J Alzheimers Dis. 2020;75(3):891\u2013902.","journal-title":"J Alzheimers Dis"},{"key":"2032_CR31","unstructured":"CBS. Levensverwachting; geslacht, leeftijd (per jaar en periode van vijf jaren) [Available from: https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/nl\/dataset\/37360ned\/table?dl=B2F1C. Accessed 08 Jan 2025."},{"issue":"1","key":"2032_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000265553","volume":"29","author":"K Andersen","year":"2010","unstructured":"Andersen K, Lolk A, Martinussen T, Kragh-S\u00f8rensen P. Very mild to severe dementia and mortality: a 14-year follow-up - the Odense study. Dement Geriatr Cogn Disord. 2010;29(1):61\u20137.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2032_CR33","doi-asserted-by":"crossref","unstructured":"Davis M, T OC, Johnson S, Cline S, Merikle E, Martenyi F, et al. Estimating Alzheimer\u2019s disease progression rates from normal cognition through mild cognitive impairment and stages of dementia. Curr Alzheimer Res. 2018;15(8):777\u201388.","DOI":"10.2174\/1567205015666180119092427"},{"key":"2032_CR34","unstructured":"Hakkaart - van Roijen L, Peeters S, Kanters T, van Baal P, Brouwer W, Drost R et al. Kostenhandleiding voor economische evaluaties in de gezondheidszorg: Methodologie en Referentieprijzen. Herziene versie 2024 ed. Diemen, 2024. p. 81."},{"key":"2032_CR35","unstructured":"Zorginstituut Nederland. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg: herziene versie 2024. Diemen: Zorginstituut Nederland; 2024. November 16, 2024. (Revision date: 16 januari 2024)\u00a0"},{"key":"2032_CR36","unstructured":"The Alzheimer's Organization. Alzheimer\u2019s organization: genetic testing. The ApoE genetic test for Alzheimer\u2019s risk. [Available from: https:\/\/www.alzheimersorganization.org\/alzheimers-test. Accessed 08 Jan 2025."},{"issue":"2","key":"2032_CR37","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3233\/JAD-191212","volume":"75","author":"RL Robinson","year":"2020","unstructured":"Robinson RL, Rentz DM, Andrews JS, Zagar A, Kim Y, Bruemmer V, et al. Costs of early stage Alzheimer\u2019s disease in the United States: cross-sectional analysis of a prospective cohort study (GERAS-US)1. J Alzheimers Dis. 2020;75(2):437\u201350.","journal-title":"J Alzheimers Dis"},{"key":"2032_CR38","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford university press; 2015."},{"issue":"4","key":"2032_CR39","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.3233\/JAD-231037","volume":"97","author":"RJ Vermeulen","year":"2024","unstructured":"Vermeulen RJ, Roudijk B, Govers TM, Rovers MM, Olde Rikkert MGM, Wijnen BFM. Prognostic information on progression to dementia: quantification of the impact on quality of life. J Alzheimers Dis. 2024;97(4):1829\u201340.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2032_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00723-1","volume":"12","author":"F Landeiro","year":"2020","unstructured":"Landeiro F, Mughal S, Walsh K, Nye E, Morton J, Williams H, et al. Health-related quality of life in people with predementia Alzheimer\u2019s disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review. Alzheimers Res Ther. 2020;12(1):154.","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"2032_CR41","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209218","volume":"102","author":"HV Nguyen","year":"2024","unstructured":"Nguyen HV, Mital S, Knopman DS, Alexander GC. Cost-effectiveness of lecanemab for individuals with early-stage Alzheimer disease. Neurology. 2024;102(7):e209218.","journal-title":"Neurology"},{"issue":"4","key":"2032_CR42","doi-asserted-by":"publisher","first-page":"928","DOI":"10.14283\/jpad.2024.67","volume":"11","author":"S Aye","year":"2024","unstructured":"Aye S, Handels R, Winblad B, J\u00f6nsson L. Optimising Alzheimer\u2019s disease diagnosis and treatment: assessing cost-utility of integrating blood biomarkers in clinical practice for disease-modifying treatment. J Prev Alzheimers Dis. 2024;11(4):928\u201342.","journal-title":"J Prev Alzheimers Dis"},{"key":"2032_CR43","doi-asserted-by":"publisher","unstructured":"Vermeulen RJ, Andersson V, Banken J, Hannink G, Govers TM, Rovers MM, Rikkert MGMO. Limited generalizability and high risk of bias in multivariable models predicting conversion risk from mild cognitive impairment to dementia: a systematic review. Alzheimers Dement. 2025;21(4):e70069. https:\/\/doi.org\/10.1002\/alz.70069.","DOI":"10.1002\/alz.70069"},{"issue":"19","key":"2032_CR44","doi-asserted-by":"publisher","first-page":"e1837","DOI":"10.1212\/WNL.0000000000207770","volume":"101","author":"RR Pittock","year":"2023","unstructured":"Pittock RR, Aakre JA, Castillo AM, Ramanan VK, Kremers WK, Jack CR Jr., et al. Eligibility for anti-amyloid treatment in a population-based study of cognitive aging. Neurology. 2023;101(19):e1837\u201349.","journal-title":"Neurology"},{"key":"2032_CR45","unstructured":"Zorginstituut Nederland. Lecanemab 2024 [Available from: https:\/\/www.horizonscangeneesmiddelen.nl\/geneesmiddelen\/lecanemab-neurologische-aandoeningen-dementie\/versie2. Accessed 09 May 2025."},{"issue":"3","key":"2032_CR46","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40120-022-00373-5","volume":"11","author":"AA Tahami Monfared","year":"2022","unstructured":"Tahami Monfared AA, Tafazzoli A, Chavan A, Ye W, Zhang Q. The potential economic value of lecanemab in patients with early Alzheimer\u2019s disease using simulation modeling. Neurol Ther. 2022;11(3):1285\u2013307.","journal-title":"Neurol Ther"},{"key":"2032_CR47","doi-asserted-by":"publisher","unstructured":"Handels R, Herring WL, Grimm S, Sk\u00f6ldunger A, Winblad B, Wimo A, J\u00f6nsson L. New IPECAD open-source model framework for the health technology assessment of early Alzheimer\u2019s disease treatment: development and use cases. Value Health. 2025;28(4):511\u2013518. https:\/\/doi.org\/10.1016\/j.jval.2024.07.009.\u00a0","DOI":"10.1016\/j.jval.2024.07.009"},{"issue":"4","key":"2032_CR48","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.3233\/JAD-170324","volume":"60","author":"RLH Handels","year":"2017","unstructured":"Handels RLH, Wimo A, Dodel R, Kramberger MG, Visser PJ, Molinuevo JL, et al. Cost-utility of using Alzheimer\u2019s disease biomarkers in cerebrospinal fluid to predict progression from mild cognitive impairment to dementia. J Alzheimers Dis. 2017;60(4):1477\u201387.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"2032_CR49","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s41669-017-0054-z","volume":"2","author":"TL Michaud","year":"2018","unstructured":"Michaud TL, Kane RL, McCarten JR, Gaugler JE, Nyman JA, Kuntz KM. Using cerebrospinal fluid biomarker testing to target treatment to patients with mild cognitive impairment: a cost-effectiveness analysis. Pharmacoeconomics. 2018;2(3):309\u201323.","journal-title":"Pharmacoeconomics"},{"key":"2032_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102725","author":"LY Lee","year":"2024","unstructured":"Lee LY, Vaghari D, Burkhart MC, Tino P, Montagnese M, Li Z, et al. Robust and interpretable AI-guided marker for early dementia prediction in real-world clinical settings. eClinicalMedicine. 2024. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102725.","journal-title":"eClinicalMedicine"},{"issue":"1","key":"2032_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14331","volume":"21","author":"M Abshire Saylor","year":"2025","unstructured":"Abshire Saylor M, Hanna V, Zhang P, Thai GH, Green CM, Cagle JG, et al. Advance care planning in adults ages 80 years and older with impaired cognition: using actual conversations to examine best practices. Alzheimers Dement. 2025;21(1):e14331.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"2032_CR52","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1111\/jgs.18495","volume":"71","author":"JL Gabbard","year":"2023","unstructured":"Gabbard JL, Carpenter JG, Ernecoff NC, Mournighan K, Cornea I, McKone M, et al. Evaluating the pragmatic characteristics of advance care planning outcome measures in dementia clinical trials: a scoping review. J Am Geriatr Soc. 2023;71(11):3595\u2013608.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"2032_CR53","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/ageing\/afr148","volume":"41","author":"L Robinson","year":"2012","unstructured":"Robinson L, Dickinson C, Rousseau N, Beyer F, Clark A, Hughes J, et al. A systematic review of the effectiveness of advance care planning interventions for people with cognitive impairment and dementia. Age Ageing. 2012;41(2):263\u20139.","journal-title":"Age Ageing"},{"issue":"3","key":"2032_CR54","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.trci.2017.03.009","volume":"3","author":"M Kunneman","year":"2017","unstructured":"Kunneman M, Smets EMA, Bouwman FH, Schoonenboom NSM, Zwan MD, Pel-Littel R, et al. Clinicians\u2019 views on conversations and shared decision making in diagnostic testing for Alzheimer\u2019s disease: the ABIDE project. Alzheimers Dement Transl Res Clin Interv. 2017;3(3):305\u201313.","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"key":"2032_CR55","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.pneurobio.2013.08.003","volume":"110","author":"JS Paulsen","year":"2013","unstructured":"Paulsen JS, Nance M, Kim JI, Carlozzi NE, Panegyres PK, Erwin C, et al. A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases. Prog Neurobiol. 2013;110:2\u201328.","journal-title":"Prog Neurobiol"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-02032-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-025-02032-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-02032-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T14:45:55Z","timestamp":1771857955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-025-02032-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":55,"alternative-id":["2032"],"URL":"https:\/\/doi.org\/10.1007\/s11357-025-02032-7","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The interactive dashboard is available at\n                      \n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interactive dashboard"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}